Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,248 shares of the company’s stock after purchasing an additional 3,499 shares during the quarter. Rhumbline Advisers owned about 0.16% of Intellia Therapeutics worth $1,938,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in Intellia Therapeutics by 71.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company’s stock valued at $1,628,000 after purchasing an additional 32,893 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after buying an additional 659,651 shares during the last quarter. Lewis Asset Management LLC raised its holdings in shares of Intellia Therapeutics by 42.5% in the third quarter. Lewis Asset Management LLC now owns 66,308 shares of the company’s stock worth $1,363,000 after buying an additional 19,775 shares during the last quarter. Finally, Atria Investments Inc lifted its stake in shares of Intellia Therapeutics by 24.3% during the third quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock worth $475,000 after buying an additional 4,511 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 29,000 shares of company stock valued at $352,551 over the last quarter. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Stock Down 6.3 %

Shares of NASDAQ NTLA opened at $9.45 on Tuesday. The firm has a market cap of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80. The company’s 50-day simple moving average is $10.80 and its 200-day simple moving average is $15.46. Intellia Therapeutics, Inc. has a 52-week low of $8.96 and a 52-week high of $33.28.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Citigroup increased their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday. Chardan Capital decreased their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a report on Friday. BMO Capital Markets reduced their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Finally, William Blair reaffirmed a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.12.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.